Testicular cancer is a malignant neoplasm arising from germ cells or, less commonly, stromal cells of the testis, most frequently presenting as a painless scrotal mass in young men aged 15–35 years.

Testicular Cancer

2. Epidemiology

Subtype	Peak Age	Notes
Seminoma	Median ~40 years (30–50)	Occurs in older men relative to NSGCT ^[2]
Teratoma/NSGCT	Younger males (20–35), can be prepubertal	^[2]
Mixed GCT	20–40 years	Contains both seminomatous and non-seminomatous elements
Testicular lymphoma	> 60 years	Most common cause of testicular mass in males > 60y ^[2]
Sex cord-stromal tumours	More common in prepubertal males ^[2]
Yolk sac tumour	Most common testicular tumour in children < 3 years

Risk factors include ^[1]^[2]^[3]:

Risk Factor	Mechanism / Explanation	Relative Risk
Cryptorchidism (undescended testis)	The undescended testis is exposed to higher core body temperature (37°C vs. 33°C in the scrotum), impairing normal germ cell maturation and promoting germ cell neoplasia in situ (GCNIS). Even after orchidopexy, the risk persists (though reduced if performed before puberty). The ipsilateral testis carries the greatest risk, but the contralateral normally-descended testis also has a slightly elevated risk.	3–50× increased risk ^[2]
Contralateral testicular cancer	Prior GCT indicates field effect / genetic susceptibility; 2–5% lifetime risk of contralateral tumour	^[2]
Hypospadias	Associated with disorders of sex development / androgen signalling; suggests underlying testicular dysgenesis	^[2]
Extragonadal GCT	Shared germ cell origin; indicates predisposition to germ cell malignancy	^[2]
Family history	Brothers of affected males have 8–10× risk; sons of affected fathers ~4× risk. Suggests genetic susceptibility (KITLG, DMRT1, TERT loci).	^[2]
Gonadal dysgenesis	Abnormal testicular development (e.g. 46,XY DSD) → disordered germ cell maturation → GCNIS	^[1]
Androgen insensitivity syndrome	Defective androgen receptor → abnormal germ cell milieu → GCNIS in intra-abdominal gonads	^[1]
HIV infection	Immunosuppression may impair immune surveillance against neoplastic germ cells; also associated with seminoma specifically	^[1]
Testicular microlithiasis	Multiple calcifications on ultrasound; marker of disordered germ cell turnover. Controversial as independent RF; significant only when combined with other RFs	Low
Infertility / subfertility	Both conditions share the common pathway of testicular dysgenesis syndrome (TDS)	Modestly increased
Previous testicular atrophy (e.g. mumps orchitis)	Germ cell damage and aberrant regeneration may promote GCNIS	Modest

Testicular Dysgenesis Syndrome (TDS)

Many risk factors for testicular cancer (cryptorchidism, hypospadias, subfertility, testicular cancer itself) cluster together as the Testicular Dysgenesis Syndrome. The unifying hypothesis is that abnormal fetal gonadal development (from genetic and/or environmental factors such as endocrine disruptors) leads to disordered germ cell maturation, which manifests as GCNIS — the universal precursor of adult-type testicular GCTs.

Exam Pearl

A common mistake is thinking orchidopexy for cryptorchidism eliminates the cancer risk. It does not — it reduces the risk (especially if done before puberty/age 12) and makes the testis palpable for self-examination, but the intrinsic germ cell abnormality persists. Also remember the contralateral normally-descended testis also has elevated risk — it's not just about the undescended one.

3. Anatomy and Function

Normal Cell	Function	Tumour Arising
Germ cells (spermatogonia)	Spermatogenesis	GCTs (seminoma, NSGCT)
Sertoli cells	Support/nurse germ cells, secrete inhibin, form blood-testis barrier	Sertoli cell tumour
Leydig cells (interstitial cells)	Secrete testosterone (in response to LH)	Leydig cell tumour

4. Etiology and Pathophysiology

4.3 Pathophysiology of Individual Subtypes

5. Classification

Classification of testicular tumours ^[1]:

Category	Prevalence	Subtypes
Germ Cell Tumours	95%
— Seminoma	~40%	Pure seminoma
— NSGCT	~55% (includes mixed)	Embryonal carcinoma, Choriocarcinoma, Yolk sac tumour, Teratoma (mature/immature), Teratoma with malignant/somatic transformation, Mixed germ cell tumour
Sex Cord-Stromal Tumours	~5%	Sertoli cell tumour, Leydig cell tumour, Granulosa cell tumour, Mixed types (Sertoli-Leydig cell tumour), Gonadoblastoma
Mixed Germ Cell and Stromal Tumours	Rare
Paratesticular tumours	Variable	Lymphoma, Leukaemia, Mesothelioma, Epithelial tumours

^[1]^[2]

This is the most important clinical distinction because it determines management:

Feature	Seminoma	NSGCT
Peak age	30–50 (older)	20–35 (younger)
AFP	Never elevated	May be elevated
β-hCG	Mildly elevated in ~10–15%	May be markedly elevated (esp. choriocarcinoma)
LDH	May be elevated	May be elevated
Spread pattern	Lymphatic > haematogenous	Both lymphatic AND haematogenous
Radiosensitivity	Exquisitely radiosensitive	Not as radiosensitive
Chemosensitivity	Highly chemosensitive	Highly chemosensitive
Natural history	Indolent, often localised	More aggressive, earlier distant metastasis

The AFP Rule

If AFP is elevated, the tumour is classified as NSGCT regardless of histology. Even if the pathologist calls it "pure seminoma" on biopsy, an elevated AFP means there must be a non-seminomatous element that was either not sampled or is too small to see histologically. This changes management significantly.

Testicular cancer staging is unique because it incorporates serum tumour markers (S) into the staging system — it is the only solid tumour that does this.

T — Primary Tumour (based on pathology after orchidectomy):

Stage	Description
pTis	GCNIS (intratubular)
pT1	Limited to testis and epididymis; no lymphovascular invasion (LVI); may invade tunica albuginea but NOT tunica vaginalis
pT2	Limited to testis and epididymis WITH LVI, or invades tunica vaginalis
pT3	Invades spermatic cord
pT4	Invades scrotum

N — Regional Lymph Nodes (retroperitoneal para-aortic nodes):

Stage	Description
N0	No LN metastasis
N1	LN mass ≤ 2 cm
N2	LN mass 2–5 cm
N3	LN mass > 5 cm

M — Distant Metastases:

Stage	Description
M0	No distant metastasis
M1a	Non-regional LN or pulmonary metastasis
M1b	Non-pulmonary visceral metastasis (liver, brain, bone)

S — Serum Tumour Markers (post-orchidectomy):

Stage	LDH	β-hCG (mIU/mL)	AFP (ng/mL)
S0	Normal	Normal	Normal
S1	< 1.5× ULN	< 5,000	< 1,000
S2	1.5–10× ULN	5,000–50,000	1,000–10,000
S3	> 10× ULN	> 50,000	> 10,000

Stage Grouping (simplified):

Stage	T	N	M	S
I	Any T	N0	M0	S0-S1
IA	pT1	N0	M0	S0
IB	pT2-T4	N0	M0	S0
IS	Any T	N0	M0	S1-S3 (markers rising post-orchidectomy)
II	Any T	N1-N3	M0	S0-S1
IIA	Any T	N1	M0	S0-S1
IIB	Any T	N2	M0	S0-S1
IIC	Any T	N3	M0	S0-S1
III	Any T	Any N	M1	Any S
IIIA	Any T	Any N	M1a	S0-S1
IIIB	Any T	Any N	M0-M1a	S2
IIIC	Any T	Any N	M0-M1a	S3, or M1b any S

The International Germ Cell Cancer Collaborative Group (IGCCCG) classifies metastatic GCTs into good, intermediate, and poor prognosis groups — this determines chemotherapy intensity:

Seminoma (no poor-prognosis category):

Prognosis	Criteria	5-yr OS
Good	Any primary site, no non-pulmonary visceral mets, normal AFP, any β-hCG, any LDH	~86%
Intermediate	Any primary site, non-pulmonary visceral mets present, normal AFP	~72%

NSGCT:

Prognosis	Criteria	5-yr OS
Good	Testis/retroperitoneal primary, no non-pulmonary visceral mets, AFP < 1000, β-hCG < 5000, LDH < 1.5× ULN	~92%
Intermediate	Testis/retroperitoneal primary, no non-pulmonary visceral mets, AFP 1000–10000 OR β-hCG 5000–50000 OR LDH 1.5–10× ULN	~80%
Poor	Mediastinal primary, OR non-pulmonary visceral mets, OR AFP > 10000 OR β-hCG > 50000 OR LDH > 10× ULN	~48%

6. Clinical Features

6.1 Symptoms

The classic presentation is a painless, hard testicular lump or swelling in a young man. However, the clinical picture varies based on stage and histological subtype.

Symptom	Frequency	Pathophysiological Basis
Painless testicular swelling / lump	~80–90% — most common presentation	Gradual tumour growth within the tunica albuginea produces a firm, non-tender mass. Pain fibres are sparse in testicular parenchyma, so growth is often insidious and painless.
Testicular heaviness / dragging sensation	Common	Increasing weight of the tumour (can reach several hundred grams) exerts traction on the spermatic cord.
Testicular pain / discomfort	~10–20%	Can occur due to: (1) haemorrhage within the tumour → sudden capsular distension; (2) infarction/necrosis of the tumour; (3) associated epididymo-orchitis. This can misleadingly suggest benign pathology.
Scrotal skin changes	Rare (unless locally advanced — pT4)	Tumour breaching the tunica albuginea, tunica vaginalis, and then scrotum

Beware the Misdiagnosis

Up to 25% of testicular cancers are initially misdiagnosed as epididymitis, orchitis, hydrocele, or trauma. If a young man is treated for "epididymitis" and the swelling does not resolve within 2 weeks of antibiotics, always get an urgent ultrasound to rule out testicular cancer. Delay in diagnosis worsens prognosis.

Non-seminoma is more likely to spread to retroperitoneal lymph nodes and to distant areas such as the liver, lung, bone and brain via the bloodstream ^[1].

Symptom	Site of Metastasis	Pathophysiological Basis
Back pain / flank pain	Retroperitoneal lymphadenopathy	Bulky para-aortic lymph nodes compress or infiltrate the psoas muscle, lumbar nerve roots, or ureteric obstruction causing hydronephrosis
Abdominal mass / bloating	Retroperitoneal lymphadenopathy	Large nodal masses can be palpable or cause abdominal distension
Cough, dyspnoea, haemoptysis	Pulmonary metastases	Direct haematogenous spread (especially NSGCT/choriocarcinoma). "Cannonball" metastases on CXR
Bone pain	Bone metastases	Haematogenous spread with periosteal stretching and pathological fractures
Headache, seizures, focal neurological deficits	Brain metastases	Haematogenous spread, especially choriocarcinoma (which has tropism for brain vasculature due to its trophoblastic nature)
Neck mass / supraclavicular lymphadenopathy	Left supraclavicular node (Virchow's node)	Retrograde lymphatic spread from para-aortic nodes via thoracic duct
Lower limb oedema	IVC compression / thrombosis	Massive retroperitoneal disease or direct IVC invasion
Dysphagia, superior vena cava syndrome	Mediastinal lymphadenopathy	Thoracic nodal involvement (particularly with primary mediastinal GCT)

Symptom	Mechanism
Gynaecomastia	β-hCG (from choriocarcinoma or seminoma with syncytiotrophoblasts) has structural homology with LH → stimulates Leydig cells → increased testosterone → peripheral aromatisation to oestradiol → breast glandular proliferation. Also, β-hCG itself can directly stimulate breast tissue via hCG receptors. Suspect testicular tumour in gynaecomastia workup ^[5].
Loss of libido, erectile dysfunction	(1) Hormonal: Leydig cell tumour producing excess oestrogen; (2) β-hCG-mediated oestrogen excess; (3) Psychological factors
Precocious puberty (in children)	Leydig cell tumour producing excess testosterone → virilizing ^[2]
Infertility	(1) Destruction of testicular parenchyma by tumour; (2) Hormonal disruption (oestrogen excess suppressing GnRH/LH/FSH); (3) Sertoli cell tumour producing inhibin → suppressed FSH
Weight loss, night sweats, fatigue	Non-specific systemic effects of malignancy (cytokine-mediated: TNF-α, IL-6)

6.2 Signs

The systematic approach to examining a scrotal mass is essential and frequently tested:

Step 1: Can you get above the swelling?

NO → Inguinoscrotal swelling (hernia or communicating hydrocele — the mass extends into the inguinal canal)
YES → True scrotal swelling — proceed to next step

Step 2: Is the swelling separable from the testis?

YES → Epididymal or paratesticular in origin (e.g., epididymal cyst, chronic epididymitis, varicocele)
NO → Testicular in origin — proceed to next step

Step 3: Does it transilluminate?

YES → Cystic/fluid-filled (hydrocele, cyst of epididymis)
NO → Solid mass (tumour, haematocele, syphilitic gumma, leukaemic infiltrate)

Findings in testicular cancer:

You CAN get above the swelling
The mass is NOT separable from the testis
It does NOT transilluminate (opaque)
It is firm/hard
Usually non-tender

Sign	Description	Pathophysiological Basis
Firm, smooth testicular enlargement	Typically associated with seminoma ^[2]	Homogeneous tumour growth expanding the testis symmetrically
Hard, irregular testicular mass	More suggestive of NSGCT or mixed GCT	Heterogeneous tumour with necrosis, haemorrhage, and calcification
Non-tender mass	Most common	Slow tumour growth without acute capsular distension; sparse pain fibres in testicular parenchyma
Loss of normal testicular landmarks	Cannot separately palpate the epididymis from the testis	Tumour engulfs the epididymis and normal testicular contour
Reactive hydrocele	Present in ~10–15%	Tumour irritates the visceral tunica vaginalis → serous exudation into the tunica vaginalis cavity
Heavy testis	Increased weight on palpation	Solid tumour is denser than normal parenchyma
Secondary hydrocele (opaque)	Small tumour hidden behind the fluid	Inflammatory exudate from tumour surface

Sign	Mechanism
Gynaecomastia	β-hCG-mediated oestrogen production (see above); testicular USG and tumour markers (AFP, β-hCG) are part of the gynaecomastia workup ^[5]
Supraclavicular lymphadenopathy (especially left — Virchow's node)	Retrograde lymphatic spread from retroperitoneal nodes via thoracic duct
Abdominal mass	Bulky retroperitoneal lymphadenopathy
Hepatomegaly	Liver metastases (haematogenous spread, especially NSGCT)
Lower limb oedema (bilateral or unilateral)	IVC obstruction by retroperitoneal mass or tumour thrombus
Absent testis on examination (post-orchidectomy)	If patient has already undergone orchidectomy
Signs of hyperthyroidism (very rare)	β-hCG has structural similarity to TSH → can cause biochemical/clinical hyperthyroidism when β-hCG levels are very high (usually choriocarcinoma)
Painless testicular enlargement (in ALL/leukaemia)	Leukaemic infiltration of the testis — a sanctuary site ^[4]

Examination Pearls for Exams

When examining a testicular lump:

Always examine BOTH testes — compare size, consistency, contour
Always examine the abdomen — for retroperitoneal masses, hepatomegaly
Always examine the chest — gynaecomastia, respiratory signs of lung mets
Always examine the supraclavicular fossae — lymphadenopathy
Always examine for signs of metastatic disease — lower limb oedema, focal neurology

Remember the differential diagnosis of testicular swelling table ^[1]:

Can get above, non-tender, opaque, inseparable from testis = Testicular tumour (until proven otherwise)

Testicular GCTs are among the few solid tumours with reliable serum tumour markers that are used for diagnosis, staging, prognostication, and monitoring treatment response.

Marker	Normal Value	Produced By	Half-Life	Clinical Significance
AFP (α-fetoprotein)	< 10 ng/mL	Yolk sac elements, embryonal carcinoma (hepatocytes in embryo)	5–7 days	Elevated in NSGCT; NEVER elevated in pure seminoma. If elevated → NSGCT regardless of histology.
β-hCG (β-human chorionic gonadotropin)	< 5 mIU/mL	Syncytiotrophoblastic cells (choriocarcinoma > embryonal > seminoma with syncytiotrophoblasts)	24–36 hours	Elevated in choriocarcinoma (markedly), embryonal carcinoma, and ~10–15% of seminomas.
LDH (lactate dehydrogenase)	Normal range	Non-specific — reflects tumour burden, cell turnover	N/A	Correlates with tumour volume. Used in staging (S classification) and IGCCCG prognostication. Non-specific (elevated in many conditions).
PLAP (placental alkaline phosphatase)	Low	Seminoma cells	N/A	Used in immunohistochemistry (IHC) for seminoma diagnosis; less useful as a serum marker due to high false-positive rates (smokers).

Expected marker profiles by subtype:

Subtype	AFP	β-hCG	LDH
Seminoma	Normal	±↑ (mild, ≤ 10–15%)	±↑
Embryonal carcinoma	±↑	±↑	±↑
Yolk sac tumour	↑↑↑	Normal	±↑
Choriocarcinoma	Normal	↑↑↑	±↑
Teratoma (pure)	Normal	Normal	Normal
Mixed GCT	Variable	Variable	Variable

Marker Half-Lives and Post-Orchidectomy Kinetics

After radical orchidectomy, markers should fall according to their half-lives (AFP: 5–7 days; β-hCG: 24–36 hours). If markers fail to normalise or rise post-orchidectomy, this indicates:

Residual/metastatic disease
Stage IS disease (marker-positive, imaging-negative) This is why post-orchidectomy markers are mandatory for accurate staging.

Understanding spread patterns connects back to the anatomy and determines staging and management:

Route	Details	Typical Subtype
Local	Tumour grows within testis → invades tunica albuginea → tunica vaginalis → epididymis → spermatic cord → scrotum (rare)	All types
Lymphatic (primary route for seminoma)	Follows testicular lymphatics → para-aortic (retroperitoneal) nodes at L1-L3 → cisterna chyli → thoracic duct → left supraclavicular (Virchow's) node	Seminoma predominantly ^[2]
Haematogenous (primary route for NSGCT)	Via testicular veins → lungs (most common distant site) > liver > brain > bone	NSGCT, especially choriocarcinoma ^[1]
Trans-scrotal (iatrogenic)	If scrotum is violated by biopsy or scrotal orchidectomy → inguinal lymph node seeding	Iatrogenic — must be avoided

Right vs. Left Lymphatic Drainage

Right testis: drains to interaortocaval and precaval nodes (at L1-L3), then to right paracaval nodes
Left testis: drains to left para-aortic and preaortic nodes

Crossover can occur: left-sided tumours can drain to the right, but right-sided tumours almost never drain to the left (the aorta acts as a barrier). This has implications for surgical templates in retroperitoneal lymph node dissection (RPLND).

9. Special Considerations

GCTs can rarely arise in extragonadal sites (mediastinum, retroperitoneum, pineal gland) from misplaced primordial germ cells that failed to migrate to the gonad during embryogenesis
Mediastinal primary NSGCT has the worst prognosis (poor-risk IGCCCG)
Always perform testicular USS to rule out occult testicular primary before diagnosing an "extragonadal" GCT

High Yield Summary

Definition: Malignant neoplasm of the testis; > 95% are germ cell tumours (GCTs).

Epidemiology: Most common solid malignancy in males 15–35; 5-year survival > 95%.

Risk Factors: Cryptorchidism (3–50×), contralateral testicular cancer, family history, hypospadias, gonadal dysgenesis, androgen insensitivity, HIV.

Pathogenesis: GCNIS (the precursor) → driven by isochromosome 12p → diverges into seminoma (spermatocytic path) or NSGCT (embryonic differentiation path).

Seminoma: Older men, indolent, lymphatic spread, radiosensitive, AFP NEVER elevated, β-hCG mild in 10–15%.

NSGCT: Younger men, aggressive, haematogenous + lymphatic spread. Subtypes: embryonal carcinoma (stem cell), yolk sac (AFP↑, most common in children), choriocarcinoma (β-hCG↑↑↑, haematogenous), teratoma (3 germ layers, chemo-resistant).

AFP Rule: If AFP is elevated, it is NSGCT regardless of histology.

Lymphatic Drainage: Para-aortic nodes (L1-L3) — NOT inguinal (unless scrotal violation).

Clinical Features: Painless, hard, non-transilluminating testicular mass inseparable from the testis. Metastatic symptoms: back pain (retroperitoneal nodes), cough/haemoptysis (lung mets), gynaecomastia (β-hCG), neurological symptoms (brain mets).

Markers: AFP (yolk sac/embryonal, half-life 5–7d), β-hCG (choriocarcinoma, half-life 24–36h), LDH (tumour burden).

Staging: TNM + S (unique serum marker stage). IGCCCG for metastatic prognostication.

Never do: Transscrotal biopsy or scrotal orchidectomy (seeds inguinal nodes).

Always do: Radical inguinal orchidectomy, sperm banking before treatment.

Active Recall - Testicular Cancer (Definition to Clinical Features)

Differential Diagnosis of a Testicular Mass / Testicular Cancer

The differential diagnosis of testicular cancer is essentially the differential of a scrotal mass or scrotal swelling. The clinical approach is systematic — you use a handful of bedside examination steps to narrow down the possibilities. Let's build this from first principles.

This is the master table for scrotal swelling, organized by examination findings ^[1]^[6]^[10]:

Can Get Above?	Separable from Testis?	Transillumination	Tenderness	Differential Diagnosis
Cannot get above	Testis palpable	Opaque	Tender / Non-tender	Indirect inguinal hernia (cough impulse +, reducible)
Cannot get above	Testis not palpable	Transilluminable	Non-tender	Communicating hydrocele (patent processus vaginalis)
Can get above	NOT separable from epididymis	Opaque	Tender	Testicular torsion, Torsion of appendix testis/epididymis, Epididymo-orchitis, Acute haematocele
Can get above	NOT separable from epididymis	Opaque	Non-tender	Testicular tumour, Chronic haematocele, Syphilitic gumma, Leukaemic infiltrate
Can get above	NOT separable from epididymis	Transilluminable	Non-tender	Hydrocele (non-communicating)
Can get above	Separable from epididymis	Opaque	Tender	Epididymo-orchitis
Can get above	Separable from epididymis	Opaque	Non-tender	TB epididymis
Can get above	Separable from epididymis	Transilluminable	Non-tender	Cyst of epididymis (spermatocele)

^[1]^[6]

3. Differential Diagnosis Discussed in Detail — By Category

3.1 Painful Scrotal Swelling (Acute Scrotum)

These are the conditions that may mimic testicular cancer when it presents with pain (~10–20% of testicular cancers present with pain due to intratumoral haemorrhage or infarction) ^[1].

Condition	Key Feature	Why It Mimics
Henoch-Schönlein Purpura (HSP)	Purpuric rash on lower limbs/buttocks, arthralgia, abdominal pain, haematuria; scrotal involvement in ~15% of boys	IgA vasculitis causes scrotal oedema and pain
Fournier's Gangrene	Necrotizing fasciitis of perineum; toxic, crepitus, rapidly spreading cellulitis	Rare but life-threatening; usually in diabetics/immunocompromised
Trauma	Clear history	Direct injury to testis
Orchitis (e.g. mumps)	Exquisitely tender, indurated; occurs 5 days after parotitis in postpubertal patients ^[6]	Viral orchitis without epididymitis

3.2 Painless Scrotal Swelling (The Key Differential for Testicular Cancer)

This is the differential that matters most, because testicular cancer typically presents as a painless mass.

When both sides are swollen, think differently:

Condition	Mechanism
Scrotal oedema	Generalised oedema (nephrotic syndrome, heart failure, liver failure) → fluid accumulates in dependent scrotal tissue ^[6]
Bilateral hydrocele	Can occur in fluid overload states
Bilateral testicular lymphoma	Commonly bilateral ^[2] — the most important bilateral testicular mass in an elderly man
Bilateral leukaemic infiltrate	Sanctuary site relapse in ALL
Bilateral varicocele	Less common; 33% of varicoceles are bilateral ^[14]

This is a high-yield way to organise the DDx because the likely diagnosis changes dramatically with age:

Age Group	Most Likely Testicular Mass	Other Considerations
Neonates	Hydrocele (communicating), testicular torsion (extravaginal)	Inguinal hernia
Children (< 12 years)	Yolk sac tumour (most common paediatric testicular malignancy), torsion of appendix testis, testicular torsion	Teratoma (benign in children), rhabdomyosarcoma (paratesticular)
Adolescents (12–18)	Testicular torsion (peak age), GCTs (especially teratoma/mixed)	Epididymo-orchitis (STIs)
Young adults (18–40)	Testicular GCT (seminoma or NSGCT) — the classic age group	Epididymo-orchitis, varicocele, hydrocele
Middle-aged (40–60)	Seminoma (peak ~40), spermatocele, hydrocele	Secondary varicocele (investigate for renal tumour)
Elderly ( > 60)	Testicular lymphoma (most common testicular mass at this age) ^[2]	Hydrocele, epididymal tumour, metastasis from other primary

When serum markers are available, they help narrow the differential among testicular malignancies:

AFP	β-hCG	LDH	Most Likely Diagnosis
Normal	Normal	Normal	Pure teratoma, sex cord-stromal tumour, lymphoma, benign conditions
Normal	Mildly ↑	±↑	Seminoma (10–15% produce low-level β-hCG)
↑	±↑	±↑	NSGCT (yolk sac tumour, embryonal carcinoma, mixed GCT)
Normal	↑↑↑	±↑	Choriocarcinoma
↑↑↑	Normal	±↑	Yolk sac tumour
↑	Any value	Any	NSGCT regardless of histology — AFP is NEVER elevated in pure seminoma ^[1]^[9]

The Golden Rule of AFP

If the pathologist reports "pure seminoma" but AFP is elevated → it is NSGCT until proven otherwise. The elevated AFP means there is a non-seminomatous component (likely yolk sac) that the pathologist missed on sampling. This changes management completely. AFP is NEVER elevated in pure seminoma ^[1].

Feature	Testicular Cancer	Epididymo-orchitis	Testicular Torsion	Hydrocele
Age	15–35 (GCT), > 60 (lymphoma)	Any age	12–18 (peak)	Any age
Onset	Gradual (weeks–months)	Gradual (days)	Sudden (minutes–hours)	Gradual (months–years)
Pain	Usually painless (~80%)	Painful	Agonizing	Painless
Tenderness	Non-tender	Tender	Exquisitely tender	Non-tender
Transillumination	Opaque	Opaque	Opaque	Transilluminable
Separable from testis	No	Early: yes; Late: no	No	No (testis obscured)
Cremasteric reflex	Present	Present	Absent	Present
Prehn's sign	N/A	Positive (relief with elevation)	Negative	N/A
Fever / dysuria	No	Yes	± mild	No
Scrotal skin	Normal (unless pT4)	Erythematous, warm	Erythematous, oedematous	Normal
Ultrasound	Solid intratesticular mass	Enlarged, hyperaemic epididymis ± testis	Whirlpool sign, absent blood flow	Anechoic fluid collection
Tumour markers	± ↑AFP, β-hCG, LDH	Normal	Normal	Normal

Sometimes patients are referred with a "testicular lump" that turns out to be something else entirely:

Condition	Why It May Be Confused	How to Distinguish
Inguinal hernia extending into scrotum	Large scrotal swelling	Cannot get above the swelling; cough impulse; bowel sounds; reducible
Scrotal wall pathology (sebaceous cyst, lipoma)	Palpable lump in scrotal area	Separate from testis; moves with skin; superficial
Referred pain from renal colic	Pain radiating to testis/scrotum	Testis is normal on examination; ureteric stone on CT-KUB
Idiopathic scrotal oedema	Bilateral scrotal swelling	No discrete mass; pitting oedema; investigate for systemic cause

High Yield Summary

Approach to scrotal mass: (1) Can you get above it? → (2) Separable from testis? → (3) Transilluminates? → (4) Tender?

Testicular cancer profile: Can get above, inseparable from testis, opaque, non-tender, firm/hard.

Top mimics: Epididymo-orchitis (most common misdiagnosis — apply 2-week rule), testicular torsion (surgical emergency — absent cremasteric reflex, high-riding testis), hydrocele (transilluminable — but always USS to exclude underlying tumour).

By age: Children → yolk sac tumour, torsion; Young adults → GCT; Elderly → lymphoma (bilateral!).

Reactive hydrocele: 10–15% of testicular cancers have a secondary hydrocele — every adult hydrocele needs ultrasound.

AFP rule: If AFP elevated → NSGCT regardless of histology.

Varicocele red flag: New non-decompressing varicocele (especially right-sided) → investigate for retroperitoneal/renal pathology.

Leukaemic infiltrate: Testis is a "sanctuary site" in ALL due to the blood-testis barrier.

Active Recall - Differential Diagnosis of Testicular Cancer

References

^[1] Senior notes: felixlai.md (Testicular cancer section — Differential diagnosis of testicular swelling) ^[2] Senior notes: Ryan Ho Urogenital.pdf (Section 11.2.5 Testicular Tumours, p.235) ^[4] Senior notes: Ryan Ho Haemtology.pdf (Section 3.2.1.2 Acute Lymphoid Leukaemia, p.60) ^[6] Senior notes: Ryan Ho Fundamentals.pdf (Scrotal examination approach, p.118; Section 3.5.10 Scrotal Swelling, p.378) ^[9] Senior notes: maxim.md (Testicular tumour — Investigations and clinical features) ^[10] Senior notes: Ryan Ho Urogenital.pdf (Section 11.2.3 Testicular Torsion, p.233) ^[11] Senior notes: felixlai.md (Testicular torsion section) ^[12] Lecture slides: GC 203. The child needs an operation Common emergencies and surgery in childhood.pdf (p.34 — Differential diagnosis of acute scrotum) ^[13] Senior notes: Ryan Ho Urogenital.pdf (Section 11.2.2 Hydrocele, p.232) ^[14] Senior notes: felixlai.md (Varicocele section)

Diagnostic Criteria, Algorithm, and Investigation Modalities

3. History Taking

A thorough history should cover the following domains ^[1]^[6]:

Domain	Key Questions	Rationale
Scrotal mass	Onset, duration, progression, unilateral/bilateral	Gradual painless growth over weeks–months favours tumour; sudden onset favours torsion/haematocele
Pain	Presence, character, radiation	~10% of testicular cancers present with pain (intratumoral haemorrhage/necrosis); distinguish from torsion (agonizing, sudden) and epididymitis (gradual, + dysuria)
Heaviness/dragging	Present?	Suggests increasing tumour mass pulling on spermatic cord
Prior treatment for "epididymitis"	Was antibiotics given? Did swelling resolve?	Non-resolving swelling after 2 weeks of antibiotics = testicular cancer until proven otherwise
Trauma history	Recent scrotal trauma?	Trauma may draw attention to a pre-existing tumour; also consider haematocele

Symptom	Metastatic Site
Back pain / flank pain	Retroperitoneal LN, psoas muscle involvement
Cough, dyspnoea, haemoptysis	Pulmonary metastases
Abdominal pain, anorexia, nausea, vomiting, GI bleeding	Retroduodenal metastasis, bulky retroperitoneal disease ^[1]
Neck mass	Supraclavicular LN metastasis ^[1]
Bone pain	Bone metastases
Neurological symptoms	CNS involvement (cerebral, spinal cord, peripheral nerve root) ^[1]
Lower extremity oedema	IVC obstruction or thrombosis ^[1]
Gynaecomastia / breast tenderness	β-hCG-producing tumour (choriocarcinoma)

4.1 Testicular Examination [1][6][9]

Inspection ^[1]:

Groin or scrotal scars (previous orchidopexy? previous surgery?)
Groin or scrotal swelling (asymmetry, erythema)

Palpation (bimanual) ^[1]:

Ask for any pain and start with the normal contralateral testis ^[1] — this is important both for comparison and for courtesy
Assess: Size / Border / Consistency / Tenderness / Mobility ^[1]
- Normal testis is homogeneous in consistency, non-tender and freely movable ^[1]
- Testicular tumour is hard, nodular, irregular and non-tender ^[1]

Systematic four-question approach ^[6]:

Question	What You're Determining	How to Assess
Is the swelling tender?	Inflammatory (torsion, infection) vs neoplastic	Gentle palpation
Can you get above it?	Scrotal origin vs inguinoscrotal (hernia, communicating hydrocele)	Place fingers above the mass at the neck of the scrotum in standing position
Is it separable from the testis?	Testicular vs epididymal/paratesticular origin	Feel along the testicular-epididymal groove superiorly
Does it transilluminate?	Fluid-filled (hydrocele, cyst) vs solid (tumour, haematocele)	Shine penlight from posterior in a dark room

Findings in testicular tumour ^[1]^[6]:

Can get above ✓
Inseparable from testis ✓
Opaque (does not transilluminate) ✓
Non-tender ✓
Firm / hard ✓
± Smooth, firm, fixed enlargement ± spread to epididymis/cord (10–15%) ^[2]
± Associated reactive hydrocele ^[2]

Completion of examination ^[1]:

Examine the contralateral testis — for synchronous tumour, atrophy, cryptorchidism
Abdomen and groin ^[1]:
- Para-aortic LNs are rarely palpable unless extremely large since they are located retroperitoneally ^[1]
- Inguinal LNs are not likely to be a response of testicular pathology but rather from the skin of scrotum and penis ^[1] — palpable inguinal nodes should make you think of penile cancer, scrotal skin pathology, or prior scrotal surgery/violation
- Hepatomegaly (liver metastases)
Chest: Gynaecomastia, respiratory signs of lung metastases
Supraclavicular fossae: Lymphadenopathy (especially left — Virchow's node)
Lower limbs: Oedema (IVC obstruction)

5. Investigation Modalities

USG scrotum is the initial imaging modality of choice for evaluating any testicular mass ^[1]^[2]^[6]^[9].

Why ultrasound first?

Non-invasive, readily available, no radiation
Extremely sensitive ( > 95%) for detecting intratesticular masses
Distinguishes between intratesticular vs extratesticular masses (majority of extratesticular masses are benign ^[6])
Distinguishes solid from cystic lesions
Screens the contralateral testis for synchronous tumour, microlithiasis, or occult pathology ^[1]

Key USS findings by pathology:

Condition	Ultrasound Appearance	Explanation
Seminoma	Well-defined hypoechoic lesion without cystic areas ^[1]^[6]^[9]	Homogeneous tumour composed of uniform sheets of cells; well-circumscribed growth pattern
NSGCT	Indistinct margins, inhomogeneous lesion with cystic areas and calcifications ^[1]^[6]^[9]	Heterogeneous tumour with multiple cell types, necrosis (→ cystic areas), dystrophic calcification, and haemorrhage
Testicular microlithiasis	≥ 5 echogenic 1–3 mm foci on USG → strongly associated with presence of CA testis ^[2]	Multiple tiny calcifications within the seminiferous tubules representing degenerated intratubular debris; marker of disordered germ cell turnover and GCNIS
Hydrocele	Anechoic fluid surrounding the testis	Fluid within tunica vaginalis; can be used to rule out reactive hydrocele (e.g. CA testis, orchitis) ^[6]
Epididymal cyst	Well-defined anechoic cyst separate from testis, posterosuperior	Fluid-filled cyst within the epididymis
Testicular torsion	Whirlpool sign (twisted spermatic cord), absent/reduced Doppler flow ^[6]	Torted spermatic cord appears as concentric rings; absent arterial flow on Doppler confirms ischaemia
Epididymo-orchitis	Enlarged hyperaemic epididymis ± testis on Doppler	Inflammation → increased blood flow on colour Doppler

Microlithiasis — What To Do?

Testicular microlithiasis (≥ 5 echogenic foci of 1–3 mm) is common (found in ~5% of men undergoing scrotal USS). In isolation (no other risk factors), current guidelines recommend reassurance and testicular self-examination — no routine follow-up USS is needed. However, if microlithiasis is found in a patient with other risk factors (cryptorchidism, previous GCT, contralateral tumour, atrophic testis, infertility), the risk is significant and closer surveillance is warranted ^[2].

5.2 Serum Tumour Markers — Pre-Orchidectomy (Mandatory)

Tumour markers = AFP + β-hCG + LDH ^[1]^[9]

Tumour markers are used for initial diagnosis and mainly for subsequent follow-up of disease status after primary treatment ^[1].

Feature	Detail
What it is	Glycoprotein normally produced by fetal yolk sac, liver, and GI tract
Normal value	< 10 ng/mL (in non-pregnant adults)
Half-life	5–7 days
Elevated in	Yolk sac tumour (main source), embryonal carcinoma, mixed GCT
Key rule	AFP is NEVER elevated in pure seminoma ^[1] — if AFP is elevated with histology showing "pure seminoma", re-classify as NSGCT
Elevated in 80–85% of NSGCT ^[1]^[9]
Other causes of AFP elevation	Pregnancy, hepatocellular carcinoma (HCC), acute/chronic hepatitis, liver cirrhosis ^[1]

Why does AFP matter so much? Because it's the single marker that categorically distinguishes seminoma from NSGCT. Pure seminoma cells do not produce AFP — only yolk sac elements and hepatoid differentiation do. If AFP is elevated, there must be a non-seminomatous component, and management changes from seminoma-protocol (which includes radiotherapy options) to NSGCT-protocol (which may include RPLND) ^[1].

Feature	Detail
What it is	Glycoprotein hormone with α-subunit (shared with LH, FSH, TSH) and unique β-subunit
Why β-subunit is measured	The α-subunit is common to several pituitary hormones (LH, FSH, TSH) ^[1] — measuring total hCG would cross-react. The β-subunit is specific to hCG.
Normal value	< 5 mIU/mL (in non-pregnant males)
Half-life	24–36 hours
Elevated in < 20% of seminoma ^[1]	Low-level elevation from syncytiotrophoblastic giant cells scattered within seminoma
Elevated in 80–85% of NSGCT ^[1]^[9]	Especially choriocarcinoma (markedly elevated, often > 50,000 mIU/mL)
Other causes of β-hCG elevation	Pregnancy, gestational trophoblastic disease, trophoblastic differentiation of primary lung cancer, trophoblastic differentiation of primary gastric cancer ^[1]
Clinical effects of very high β-hCG	Gynaecomastia (LH-like activity → oestrogen production), hyperthyroidism (TSH-like activity due to α-subunit homology)

Feature	Detail
What it is	Ubiquitous cytoplasmic enzyme released by damaged/proliferating cells
Normal value	Varies by laboratory; typically 120–246 U/L
Specificity	Non-specific — elevated in many conditions (haemolysis, liver disease, MI, lymphoma, etc.)
Role in testicular cancer	Correlates with tumour burden (volume of disease) and cell turnover
Used in	S staging (AJCC) and IGCCCG prognostic classification

Histological Subtype	AFP	β-hCG	LDH
Pure seminoma	Normal	±↑ (< 20%, mild)	±↑
Embryonal carcinoma	±↑	±↑	±↑
Yolk sac tumour	↑↑↑	Normal	±↑
Choriocarcinoma	Normal	↑↑↑	±↑
Pure teratoma	Normal	Normal	Normal
Mixed GCT	Variable	Variable	Variable
Leydig / Sertoli cell tumour	Normal	Normal	Normal
Lymphoma	Normal	Normal	±↑

Marker-Negative Tumours

About 15–20% of NSGCTs have normal AFP and β-hCG. Pure teratoma and some embryonal carcinomas may not produce markers. A normal marker profile does NOT exclude testicular cancer. The diagnosis still rests on ultrasound + orchidectomy histology. Markers are extremely useful when elevated, but their absence does not rule out malignancy.

After radical inguinal orchidectomy, markers should fall according to their half-lives:

AFP (half-life 5–7 days): should halve every ~5–7 days
β-hCG (half-life 24–36 hours): should halve every ~1–1.5 days

Marker Trajectory	Interpretation	Stage
Normalises as expected	Tumour fully resected; no metastatic disease producing markers	Supports Stage I (if imaging also clear)
Falls but plateaus above normal	Residual disease (micrometastases) producing markers at a low level	Stage IS (marker-positive, imaging-negative) or higher
Rises after initial fall	Progressive residual/metastatic disease	Stage IS or higher; requires systemic treatment

Serum markers staging (S) ^[1]:

S Stage	LDH	β-hCG (mIU/mL)	AFP (ng/mL)
S0	Normal	Normal	Normal
S1	< 1.5× ULN	< 5,000	< 1,000
S2	1.5–10× ULN	5,000–50,000	1,000–10,000
S3	> 10× ULN	> 50,000	> 10,000

^[1]

Radical inguinal orchidectomy is both diagnostic and therapeutic ^[1]^[2]^[9].

Technique ^[2]:

Enter via inguinal incision (NOT scrotal) ^[2]^[9]
Clamp cord early before scrotal manipulation to prevent seeding ^[2] — the testicular vein is clamped and ligated at the level of the deep inguinal ring before the testis is mobilized. This prevents intraoperative shedding of tumour cells into the venous system.
Mobilize testis into the incision ^[2]
If doubtful, then bisect testis to confirm presence of tumour ^[2] — intraoperative frozen section can be performed if the diagnosis is uncertain (e.g., small lesion, possible benign pathology). If benign, testis-sparing surgery may be considered.
If confirmed tumour, then double ligation of cord with division at the level of the inguinal ring + removal of testis ^[2]

Why inguinal approach? ^[2]^[9]:

Inguinal approach is preferred as other approaches are associated with scrotal violation → potentially increased risk of recurrence ^[2]
Scrotal incision would seed tumour into the scrotal skin → drainage to inguinal LNs → changing the staging and treatment field ^[1]

Complications: Usually minimal morbidity, most commonly post-operative scrotal haematoma ^[2]

What does the histopathology report tell you?

The orchidectomy specimen is the definitive staging tool for the T-component of TNM. The pathologist reports:

Tumour type (seminoma, NSGCT subtypes, mixed)
Tumour size
Invasion of tunica albuginea, tunica vaginalis, rete testis, epididymis, spermatic cord, scrotal wall
Lymphovascular invasion (LVI) — critical for risk stratification of Stage I disease
Margins (particularly cord margin)
Presence of GCNIS in adjacent tissue
Immunohistochemistry: OCT3/4, PLAP (seminoma), CD30 (embryonal carcinoma), AFP (yolk sac), β-hCG (trophoblastic elements), CD117/KIT (GCNIS, seminoma)

When Can You Skip Orchidectomy?

Almost never. However, in life-threatening situations (e.g., massive pulmonary metastases with respiratory failure from choriocarcinoma), you may need to start emergency chemotherapy before orchidectomy. In this scenario, grossly elevated β-hCG ± AFP with characteristic imaging is considered diagnostic, and orchidectomy is performed after the patient is stabilised. This is the only exception.

5.4 Staging Investigations — After Orchidectomy

Once the histological diagnosis is confirmed, staging investigations are performed to determine the extent of disease.

CT thorax, abdomen and pelvis is the imaging modality of choice to evaluate the retroperitoneum ^[1].

What CT Assesses	Findings	Interpretation
Retroperitoneal (para-aortic) lymph nodes	Abnormal node is defined as > 10 mm in short axis to indicate pathological adenopathy ^[1]	Regional metastasis first appears in the retroperitoneal LNs which are the para-aortic lymph nodes ^[1]. Right-sided tumours → interaortocaval/precaval nodes; left-sided → left para-aortic/preaortic nodes.
Mediastinal / hilar lymph nodes	Enlarged nodes in mediastinum	Supradiaphragmatic nodal spread (Stage III)
Pulmonary parenchyma	Nodules — classically "cannonball" metastases	Haematogenous spread, especially NSGCT/choriocarcinoma (M1a)
Liver	Hypodense / hypervascular lesions	Hepatic metastases (M1b — non-pulmonary visceral)
Bone (incidental)	Lytic/sclerotic lesions	Osseous metastases (uncommon)
Hydronephrosis	Dilated renal pelvis/ureter	Ureteric obstruction from bulky retroperitoneal nodes

When to order	Why
Choriocarcinoma (any stage)	Choriocarcinoma has a strong tropism for cerebral vasculature; brain metastases can present as haemorrhagic lesions
Very high β-hCG ( > 50,000 mIU/mL)	High β-hCG correlates with trophoblastic differentiation and risk of CNS spread
Any neurological symptoms	Headache, seizures, focal deficits
Poor-prognosis NSGCT (IGCCCG)	Higher risk of CNS metastases

MRI brain is preferred over CT brain due to superior sensitivity for posterior fossa and small parenchymal lesions.

Investigation	Rationale
CBC with differential	Baseline before chemotherapy; detect anaemia of chronic disease, or leukaemic infiltrate
Renal function (Cr, eGFR)	Baseline before cisplatin-based chemotherapy (nephrotoxic); detect hydronephrosis from retroperitoneal disease
Liver function tests (LFT)	Baseline; detect hepatic metastases; AFP interpretation requires normal liver function (hepatitis/cirrhosis can also elevate AFP)
Electrolytes	Baseline; tumour lysis syndrome risk with bulky disease
Thyroid function	If β-hCG very high → hCG-mediated hyperthyroidism (α-subunit homology with TSH)
Sex hormone profile (testosterone, LH, FSH)	Baseline fertility assessment; endocrine tumours (Leydig/Sertoli cell); hypogonadism assessment post-orchidectomy
Blood group and save	Pre-operative preparation for orchidectomy
Coagulation profile	Pre-operative

Investigation	Why NOT
FNAC / percutaneous biopsy of testis	Risk of tumour seedling along biopsy tract into scrotal skin → drainage to inguinal LNs which are normally NOT involved in testicular cancer (testes drain to para-aortic LNs only) ^[1]^[9]
Scrotal orchidectomy / scrotal incision	Violates scrotal skin → seeds inguinal lymph node basin → changes staging and treatment field ^[2]^[9]
Open biopsy of testis through scrotum	Same principle as above

After completing all investigations, the final stage is determined using the AJCC 8th Edition TNM-S system (covered in detail in the previous section). Here is a simplified clinical staging approach:

Stage	Definition	Investigation Basis
Stage 0	Tis (GCNIS), N0, M0, S0	Orchidectomy showing GCNIS only; markers normal; CT clear
Stage I	T1-4, N0, M0, SX/S0	Orchidectomy confirms tumour; markers normalise post-op; CT clear
Stage IS	Any T, N0, M0, S1-3	Markers fail to normalise / rise post-orchidectomy despite clear imaging
Stage II	Any T, N1-3, M0, S0-1	CT shows retroperitoneal LN involvement ( > 10 mm)
Stage III	Any T, Any N, M1, S0-3	Distant metastases on CT (lung, liver, brain, bone)

^[1]

7. Special Diagnostic Scenarios

Different biology from adult GCTs
Yolk sac tumour is the most common (pure form, not mixed)
Mature teratoma in children is benign (unlike in adults)
Testis-sparing surgery may be considered in children with small tumours and normal markers
Do NOT assume adult staging/management rules apply to prepubertal tumours

High Yield Summary

Diagnostic sequence: Clinical suspicion → Scrotal USS → Serum markers (AFP, β-hCG, LDH) → Radical inguinal orchidectomy → Post-orchidectomy markers + CT TAP → Final staging.

NEVER do: FNAC, percutaneous biopsy, or scrotal orchidectomy — risk of tumour seeding to inguinal LN basin.

USS findings: Seminoma = well-defined, hypoechoic, no cystic areas. NSGCT = inhomogeneous, indistinct margins, cystic areas, calcifications. Microlithiasis (≥ 5 foci of 1–3 mm) = strongly associated with testicular cancer.

Markers: AFP (never elevated in pure seminoma; half-life 5–7d), β-hCG (< 20% seminoma, 80–85% NSGCT; half-life 24–36h), LDH (non-specific, tumour burden).

Post-orchidectomy kinetics: Markers must normalise per half-life. Failure = Stage IS (residual disease).

Staging CT: Abnormal retroperitoneal node = > 10 mm short axis. CT TAP is the modality of choice for the retroperitoneum.

PET-CT: Only for post-chemo residual masses in seminoma (not NSGCT — teratoma is PET-negative).

Orchidectomy technique: Inguinal incision → clamp cord before mobilising testis → double ligation at deep ring → remove testis and cord.

Sperm banking: Offer to ALL patients before any treatment; ~50% already have impaired spermatogenesis at baseline.

Active Recall - Diagnosis of Testicular Cancer

References

^[1] Senior notes: felixlai.md (Testicular cancer — Diagnosis section, Tumour markers, Radiological tests) ^[2] Senior notes: Ryan Ho Urogenital.pdf (Section 11.2.5 Testicular Tumours, p.235–236) ^[6] Senior notes: Ryan Ho Fundamentals.pdf (Scrotal examination approach, p.118; USG scrotum findings, p.379) ^[9] Senior notes: maxim.md (Testicular tumour — Investigations and Management sections)

Management of Testicular Cancer

Cryopreservation of sperm should be made available to all men diagnosed with testicular cancer prior to instituting therapy if they wish to preserve fertility ^[1].

Key Point	Explanation
~50% of men already have impaired spermatogenesis at baseline	Due to testicular dysgenesis syndrome — the same pathology that predisposes to cancer also impairs germ cell function ^[1]
Semen quality may further deteriorate following removal of affected testis	Loss of ~50% of testicular parenchyma
Sperm banking should be performed before radiographic diagnostic evaluation	To avoid radiation exposure of sperm ^[1] — CT scans expose the remaining testis to scatter radiation
Should be offered before chemotherapy and radiotherapy	Both are gonadotoxic; alkylating agents (cisplatin) are particularly damaging to spermatogenesis
Timing	Ideally 2–3 samples collected over 1–2 weeks before treatment (but do not delay urgent treatment for banking)

5. Management of Seminoma — By Stage

This is the most common presentation (~70–80% of seminomas). The cure rate is > 99% regardless of which option is chosen. The debate is about minimising overtreatment while maintaining cure.

Three options ^[1]^[2]:

Option	What It Involves	Rationale	Relapse Rate	Pros	Cons
Active Surveillance (preferred in 2025 guidelines)	Regular follow-up: markers + CT scans on a scheduled protocol for 5–10 years	~15–20% of Stage I seminomas harbour occult micrometastases; surveillance identifies the ~15–20% who relapse and treats them then (still curable). The remaining ~80% are spared unnecessary adjuvant treatment.	15–20% relapse (virtually all salvaged with RT or chemo)	Avoids overtreatment in 80% of patients; no treatment toxicity	Requires strict compliance with follow-up; radiation exposure from serial CT scans; patient anxiety
Adjuvant radiotherapy	Para-aortic ± ipsilateral iliac ("dog-leg") field, 20 Gy in 10 fractions	Seminoma is exquisitely sensitive to radiation therapy ^[1]^[9]. Low-dose RT sterilises occult retroperitoneal micrometastases.	~1–3% relapse	Very low relapse rate; well-tolerated	Risk of secondary radiotherapy-induced malignancies ^[1] (especially in young patients — risk of contralateral testicular cancer, GI tract cancers, sarcomas increases over decades); gonadotoxic scatter to remaining testis; rarely used as first-line in modern practice
Adjuvant single-agent carboplatin	1–2 cycles of carboplatin (AUC 7)	Systemic treatment sterilises occult micrometastases; achieves similar relapse reduction as RT without radiation-associated second cancers	~3–5% relapse	Convenient (1–2 day infusions); avoids radiation; low toxicity	Not as extensively studied long-term as surveillance or RT; risk of over-treatment in 80%

Current Practice Trend (2025)

Active surveillance is increasingly preferred as the standard of care for Stage I seminoma because:

Cure rate approaches 100% even if relapse occurs (salvage chemo is highly effective)
Avoids all adjuvant treatment toxicity in the 80% who would never relapse
Modern surveillance protocols with risk-adapted CT scanning reduce radiation exposure

However, adjuvant carboplatin or RT remain options for patients who cannot comply with rigorous surveillance schedules, or who have extreme anxiety about surveillance.

Risk factors for relapse in Stage I seminoma (guide shared decision-making):

Tumour size > 4 cm
Rete testis invasion
Lymphovascular invasion (LVI)
(These are not absolute indications for adjuvant treatment — they inform the discussion)

Adjuvant RT for stage II seminomas (exquisitely radiosensitive) ^[2]:

Stage	Treatment Options	Details
Stage IIA (LN ≤ 2 cm)	Radiotherapy (30 Gy) to para-aortic + ipsilateral iliac nodes	Cure rate > 95%. RT is highly effective for low-volume retroperitoneal disease.
Stage IIB (LN 2–5 cm)	Radiotherapy (36 Gy) OR Chemotherapy (3× BEP or 4× EP)	Both options have similar outcomes. The trend is towards chemo for IIB because larger nodal masses have higher relapse rates after RT alone.

Why does RT work so well for seminoma? Seminoma cells have a high sensitivity to DNA damage from ionising radiation. They have limited DNA repair capacity compared to NSGCT cells, possibly related to their germ cell origin (germ cells normally undergo apoptosis readily when DNA is damaged — a protective mechanism for genetic integrity).

Cisplatin-based chemotherapy for more advanced tumours ^[2]:

Risk Category (IGCCCG)	Treatment	Expected 5-yr OS
Good prognosis (majority of metastatic seminoma)	3 cycles BEP or 4 cycles EP (if bleomycin contraindicated)	~86%
Intermediate prognosis (non-pulmonary visceral mets)	4 cycles BEP	~72%

Note: There is no "poor prognosis" category for seminoma in the IGCCCG system — even metastatic seminoma has relatively favourable outcomes.

Post-chemotherapy management of residual masses in seminoma:

If residual mass < 3 cm → surveillance (most are fibrosis/necrosis)
If residual mass ≥ 3 cm → PET-CT at 6–8 weeks post-chemo
- PET-negative → surveillance
- PET-positive → further treatment (surgical resection or salvage chemotherapy)

6. Management of NSGCT — By Stage

NSGCT management differs fundamentally from seminoma because:

NSGCT is radioresistant ^[1]^[9] — RT has no role
Teratoma within NSGCT is chemoresistant — it must be surgically resected
RPLND plays a much larger role than in seminoma

Risk stratification is based on lymphovascular invasion (LVI):

LVI Status	Risk of Occult Metastases	Preferred Management	Alternative
LVI absent (low-risk)	~15% relapse rate	Active Surveillance (preferred)	Adjuvant 1 cycle BEP
LVI present (high-risk)	~50% relapse rate	Adjuvant 1 cycle BEP (reduces relapse to ~3–5%) or Primary RPLND	Active surveillance (but requires very close follow-up)

No treatment if early (stage I) — this refers to the surveillance option ^[2].

RPLND for high-risk early (stage I) NSGCTs ^[2]:

Primary nerve-sparing RPLND is an option for Stage I NSGCT (especially in centres with expertise)
Advantage: definitive pathological staging of the retroperitoneum; avoids chemotherapy in patients with pN0 disease
Disadvantage: morbidity (see below); does not address potential distant micrometastases

Why is LVI the Key Risk Factor in Stage I NSGCT?

Lymphovascular invasion means tumour cells have already entered blood vessels or lymphatic channels within the testis. This is the earliest step in metastatic dissemination. If LVI is present, there is approximately a 50% chance that microscopic disease has already seeded the retroperitoneal nodes or distant sites, even though imaging appears normal. Without adjuvant treatment, half of these patients will relapse. One cycle of BEP dramatically reduces this risk to ~3–5%.

This is a unique situation: markers are rising/not normalising after orchidectomy, but imaging shows no visible disease. The tumour is producing markers from somewhere — there must be micrometastatic disease.

Management	Rationale
Chemotherapy (3–4 cycles BEP based on IGCCCG risk)	Marker-positive disease indicates systemic micrometastases that require systemic treatment. RPLND alone would miss non-retroperitoneal micrometastases.

Stage	Options	Details
IIA (LN ≤ 2 cm, markers normal/S1)	Primary RPLND (nerve-sparing) OR Chemotherapy (3× BEP for good-risk, 4× BEP for intermediate-risk)	RPLND preferred if markers normalised and nodes small; provides definitive pathological staging. If nodes contain only teratoma → no further treatment. If viable GCT → 2 adjuvant cycles of chemo.
IIB (LN 2–5 cm)	Chemotherapy (3× BEP good-risk, 4× BEP intermediate-risk) followed by post-chemo RPLND if residual mass	Larger nodal mass = higher tumour burden → systemic treatment first
IIC (LN > 5 cm)	Chemotherapy first (as for Stage III) → post-chemo RPLND	Bulky disease requires upfront systemic treatment

Cisplatin-based chemotherapy for other more advanced tumours. Regimen depends on risk stratification and extent of tumour ^[2].

IGCCCG Risk	Regimen	Cycles	5-yr OS
Good prognosis	3 cycles BEP or 4 cycles EP	3–4	~92%
Intermediate prognosis	4 cycles BEP	4	~80%
Poor prognosis	4 cycles BEP (standard) ± consideration of dose-dense/high-dose chemo with autologous stem cell rescue in selected cases	4+	~48%

Post-chemotherapy assessment for NSGCT (critical decision point):

Scenario	Action	Rationale
Complete response (markers normalised + no residual mass on CT)	Surveillance	No residual disease to treat
Markers normalised + residual mass on CT	Post-chemotherapy RPLND (mandatory surgical resection of ALL residual masses)	Cannot distinguish fibrosis vs teratoma vs viable GCT on imaging. Teratoma is chemoresistant and will grow/transform if left in situ.
Markers rising despite chemotherapy	Salvage chemotherapy (TIP: paclitaxel + ifosfamide + cisplatin; or VeIP: vinblastine + ifosfamide + cisplatin)	First-line chemo-refractory disease; needs alternative regimen

Why is post-chemo RPLND mandatory in NSGCT but not seminoma?

The histology of post-chemo residual masses differs fundamentally between the two:

	Seminoma residual mass	NSGCT residual mass
Necrosis/fibrosis	~80%	~40–50%
Viable tumour	~10–20%	~10–15%
Teratoma	Very rare (seminoma doesn't differentiate into teratoma)	~40–50%

The key issue is teratoma. In NSGCT, post-chemo residual masses contain teratoma in ~40–50% of cases. Teratoma is chemoresistant (it doesn't respond to further cycles), can grow progressively ("growing teratoma syndrome"), and can undergo malignant transformation into non-germ-cell cancers (sarcoma, adenocarcinoma). The only way to deal with teratoma is surgical resection. In seminoma, teratoma is exceedingly rare in residual masses, so PET-CT can reliably distinguish fibrosis from viable tumour.

7. Treatment Modalities — Detailed Pharmacology and Mechanisms

7.1 Chemotherapy — BEP Regimen

BEP therapy: Bleomycin + Etoposide + Cisplatin ^[1]

This is the gold standard chemotherapy regimen for testicular GCTs. Let's break down each drug:

4 cycles EP is equivalent to 3 cycles BEP in good-prognosis disease
Used when bleomycin is contraindicated (e.g., pre-existing lung disease, age > 50 with comorbidities, prior bleomycin toxicity)

Summary of BEP schedule (standard cycle = 21 days, 3–4 cycles):

Drug	Day	Administration
Bleomycin	Day 1, 8, 15	IV bolus (30 IU)
Etoposide	Day 1–5	IV infusion (100 mg/m²)
Cisplatin	Day 1–5	IV infusion (20 mg/m²/day) with aggressive hydration

Seminoma is exquisitely sensitive to radiation therapy ^[1]^[9]. Non-seminomatous germ cell tumours are more radio-resistant ^[1].

Indication	Field	Dose	Notes
Stage I seminoma (adjuvant, if chosen)	Para-aortic ± ipsilateral iliac ("dog-leg")	20 Gy in 10 fractions	Declining use due to late second-cancer risk
Stage IIA seminoma	Para-aortic + ipsilateral iliac	30 Gy (with boost to involved nodes)	High cure rate > 95%
Stage IIB seminoma	Para-aortic + ipsilateral iliac	36 Gy	Alternative to chemotherapy
NSGCT	Not used (radioresistant)	—	—

Risk of secondary radiotherapy-induced malignancies ^[1]: This is the major concern with RT in young patients. Radiation fields to the para-aortic region expose the stomach, pancreas, kidney, bowel, and remaining testis to scatter. Long-term follow-up studies show increased rates of:

Second solid cancers (GI cancers, sarcomas) — risk increases over decades
Contralateral testicular cancer (from scatter)
Cardiovascular disease (mediastinal irradiation)

This is why there has been a strong shift towards surveillance and carboplatin over RT for Stage I seminoma.

RPLND ^[1]^[2]:

What it is: Surgical removal of the retroperitoneal lymph node-bearing tissue (fat pad) along the great vessels from the renal hilum to the bifurcation of the common iliac arteries.

Indications:

Indication	Rationale
Post-chemotherapy residual mass in NSGCT (markers normalised)	Reserved for patients with post-chemotherapy residual disease since primary chemotherapy is the treatment of choice for patients with Stage II or III disease ^[1]. Must surgically resect to differentiate fibrosis vs teratoma vs viable GCT.
High-risk Stage I NSGCT (as alternative to adjuvant chemo)	RPLND for high-risk early (stage I) NSGCTs ^[2]. Provides definitive pathological staging.
Primary treatment for Stage IIA NSGCT (markers normal)	Alternative to chemotherapy in low-volume retroperitoneal disease
Post-chemotherapy residual mass in seminoma (PET-positive or growing)	Rare indication

Key points about RPLND ^[1]:

Requires expertise and has high risk of complications ^[1]
Only reliable method to identify nodal micrometastasis given the high false-negative rate with CT ^[1]
GOLD standard for providing accurate pathological staging of the retroperitoneum ^[1]

Surgical templates:

Right-sided tumour: right-sided modified template (right paracaval, interaortocaval, preaortic)
Left-sided tumour: left-sided modified template (left para-aortic, preaortic, interaortocaval)
Full bilateral template: used for post-chemotherapy RPLND when disease is bilateral

Nerve-sparing technique:

The sympathetic postganglionic fibres (from the hypogastric plexus, T12-L3) that control antegrade ejaculation run along the aorta and cross anterior to the common iliac arteries
Damage to these fibres → retrograde ejaculation (semen goes backward into the bladder instead of forward through the urethra) → effective infertility despite normal sperm production
Nerve-sparing RPLND carefully identifies and preserves these fibres, reducing the rate of retrograde ejaculation from ~75% (non-nerve-sparing) to < 5% (nerve-sparing)

Complications of RPLND:

Complication	Mechanism	Prevention
Retrograde ejaculation (most important)	Damage to sympathetic postganglionic fibres controlling ejaculation	Nerve-sparing technique
Lymphatic leak / chylous ascites	Disruption of cisterna chyli or major lymphatics	Careful surgical technique; fat-free diet post-op
Bowel obstruction (adhesions)	Post-operative adhesion formation	Standard surgical care
Vascular injury (aorta, IVC, renal vessels)	Proximity to great vessels	Expert surgeon
Renal failure (rare)	Renal artery injury or sacrifice	Uncommon in experienced centres

For patients who relapse after first-line BEP or have refractory disease:

Regimen	Components	Indication
TIP	Paclitaxel + Ifosfamide + Cisplatin	First-line salvage for relapsed GCT
VeIP	Vinblastine + Ifosfamide + Cisplatin	Alternative salvage regimen
High-dose chemotherapy + autologous stem cell transplant (HDCT + ASCT)	High-dose carboplatin + etoposide → followed by re-infusion of previously harvested autologous stem cells	Second or third salvage; testicular germ cell tumour is an indication for autologous HSCT ^[15]. Used when conventional-dose salvage fails. The principle is to give myeloablative doses of chemo that would otherwise be fatal, then "rescue" the patient's bone marrow by re-infusing their own stored stem cells.

8. Management of Special Situations

Surveillance: serial monitoring of β-hCG, AFP within first 1–2 years (relapse > 2 years rare) ^[2].

Component	Frequency (Year 1–2)	Frequency (Year 3–5)	Frequency (Year 5+)
Physical examination	Every 2–3 months	Every 4–6 months	Annually
Serum markers (AFP, β-hCG, LDH)	Every 2–3 months	Every 4–6 months	Annually
CT abdomen/pelvis	2–4× per year (NSGCT); 2–3× per year (seminoma)	1–2× per year	As indicated
CXR	2–4× per year	1–2× per year	As indicated
Testosterone level	Annually	Annually	Annually

Why is relapse > 2 years rare? GCTs are rapidly proliferating tumours — if micrometastases are present, they grow quickly and declare themselves within the first 1–2 years. Late relapse ( > 2 years) occurs in < 5% of cases but should not be forgotten — it tends to be chemoresistant teratoma with somatic transformation.

Prognosis: 95% 5-year survival if no metastasis after adjuvant RT/chemo ^[2].

Stage	5-Year Survival
Stage I (all types)	> 99%
Stage II seminoma	> 95%
Stage II NSGCT	~90–95%
Metastatic good-prognosis (IGCCCG)	Seminoma ~86%, NSGCT ~92%
Metastatic intermediate-prognosis	Seminoma ~72%, NSGCT ~80%
Metastatic poor-prognosis (NSGCT only)	~48%

One of the most curable solid neoplasms: 5-year survival > 95%, only representing 0.1% of all male cancer deaths ^[2].

High Yield Summary

Step 1 (ALL patients): Radical inguinal orchidectomy + pre-op sperm banking.

Seminoma management:

Stage I → Surveillance (preferred) / adjuvant carboplatin (1–2 cycles AUC 7) / adjuvant RT (20 Gy). Surveillance is the modern standard.
Stage IIA–IIB → RT (30–36 Gy) or chemotherapy (3× BEP / 4× EP).
Stage IIC–III → Chemotherapy (BEP). Post-chemo residual mass ≥ 3 cm → PET-CT (if PET+ve → resect or salvage chemo).

NSGCT management:

Stage I → Surveillance (low-risk) / 1 cycle adjuvant BEP or primary RPLND (high-risk/LVI+).
Stage IS → Chemotherapy (markers not normalising post-orchidectomy).
Stage II–III → Chemotherapy (BEP, cycles based on IGCCCG risk) → post-chemo RPLND for ANY residual mass (mandatory — to resect teratoma).

Key pharmacology: BEP = Bleomycin (DNA strand breaks, pulmonary fibrosis) + Etoposide (topo-II inhibitor, secondary leukaemia) + Cisplatin (DNA crosslinks, nephro/ototoxicity). Bleomycin + high FiO2 anaesthesia = FATAL pulmonary toxicity.

RPLND: Gold standard for retroperitoneal staging. Nerve-sparing technique preserves ejaculation. Main complication = retrograde ejaculation.

Post-chemo residual mass: Seminoma → PET-CT. NSGCT → always resect (teratoma is chemo-resistant, PET-negative but still needs surgery).

Salvage: TIP or VeIP. Ultimate salvage: high-dose chemo + autologous SCT.

Active Recall - Management of Testicular Cancer

References

^[1] Senior notes: felixlai.md (Testicular cancer — Treatment section) ^[2] Senior notes: Ryan Ho Urogenital.pdf (Section 11.2.5 Testicular Tumours, p.235–236) ^[9] Senior notes: maxim.md (Testicular tumour — Management section) ^[15] Senior notes: Ryan Ho Haemtology.pdf (Section 5.2 Haematopoietic Stem Cell Transplantation, p.153)

Complications of Testicular Cancer and Its Treatment

Testicular cancer is one of the most curable solid tumours, with 5-year survival > 95% ^[2]. Paradoxically, this very curability creates a unique set of problems: the majority of patients are young men who will live for decades after treatment, which means long-term treatment-related complications become critically important — often more so than the cancer itself. Think of it this way: if you cure a 25-year-old man of his testicular cancer, he has 50+ years to develop second cancers, cardiovascular disease, infertility, and metabolic syndrome from the treatments you gave him.

The complications of testicular cancer can be logically divided into:

Complications of the disease itself (from the tumour and its metastases)
Complications of surgery (orchidectomy, RPLND)
Complications of chemotherapy (BEP regimen toxicities)
Complications of radiotherapy
Long-term survivorship complications (the most important category for exams)
Psychosocial complications

1. Complications of the Disease Itself

These are complications that arise from the tumour's local effects, metastatic spread, or paraneoplastic phenomena — occurring when the disease is undertreated, diagnosed late, or in advanced stages.

Complication	Mechanism	Clinical Significance
Testicular destruction	Tumour replaces normal parenchyma → loss of spermatogenesis and testosterone production from affected testis	Contributes to baseline subfertility (remember ~50% of men already have some degree of impaired spermatogenesis ^[1])
Intratumoral haemorrhage	Rapidly growing tumour outstrips its blood supply → central necrosis and haemorrhage → sudden capsular distension	Acute testicular pain (~10% of cases), mimicking torsion or epididymitis; can delay correct diagnosis
Secondary hydrocele	Tumour irritates the visceral tunica vaginalis → serous exudation into the tunica vaginalis cavity	Obscures the underlying tumour on physical examination; every adult hydrocele requires USS

Non-seminoma is more likely to spread to retroperitoneal LNs and to distant areas such as the liver, lung, bone and brain via the bloodstream ^[1].

Metastatic Site	Complication	Mechanism
Retroperitoneal lymph nodes	Lumbar back pain ^[1]	Bulky para-aortic lymphadenopathy compresses or infiltrates psoas muscle, lumbar nerve roots
	Ureteric obstruction → hydronephrosis → renal impairment	Enlarged nodes encase the ureter at the pelvic brim or retroperitoneum → obstructive uropathy
	Lower limb oedema	Iliac vein or IVC obstruction or thrombosis ^[1]
	Anorexia, nausea, vomiting, GI bleeding	Retroduodenal metastasis ^[1] — bulky retroperitoneal nodes compress/invade the duodenum
Lungs	Cough, dyspnoea, haemoptysis ^[1]	Parenchymal metastases ("cannonball" mets); large-volume disease replaces functional lung parenchyma ± causes pleural effusion ^[16]
	Respiratory failure	Massive pulmonary metastases (especially choriocarcinoma) — can be life-threatening at presentation
Brain	CNS symptoms (headache, seizures, focal neurological deficits) ^[1]	Haematogenous spread — particularly choriocarcinoma, which has tropism for cerebral vasculature; brain metastases may be haemorrhagic (trophoblastic tissue is inherently vascular and friable)
Bone	Bone pain, pathological fractures	Haematogenous spread with destruction of cortical bone ^[1]
Liver	Hepatomegaly, deranged LFTs	Haematogenous spread, especially NSGCT

Complication	Mechanism	Tumour Subtype
Gynaecomastia (5%) ^[1]	β-hCG has structural homology with LH → stimulates Leydig cells → ↑testosterone → peripheral aromatisation to oestradiol → breast glandular proliferation. Also β-hCG can directly stimulate breast tissue.	Choriocarcinoma, mixed GCT with trophoblastic elements, seminoma with syncytiotrophoblasts
Hyperthyroidism ^[1]	hCG and TSH have a common α-subunit and a β-subunit with considerable homology, and thus hCG has a weak thyroid-stimulating effect ^[1]. When β-hCG levels are very high ( > 50,000–100,000 mIU/mL), this TSH-like activity becomes clinically significant → excess thyroid hormone production.	Choriocarcinoma (massive β-hCG production)
Precocious puberty (children)	Leydig cell tumour → excess testosterone → premature virilisation	Leydig cell tumour
Feminisation (gynaecomastia, loss of libido, ED, infertility)	Leydig/Sertoli cell tumour → excess oestrogen (directly or via aromatisation); or oestrogen suppresses GnRH axis → ↓LH/FSH	Leydig cell tumour, Sertoli cell tumour

2. Complications of Surgery

Complications: usually minimal morbidity, most commonly post-operative scrotal haematoma ^[2].

Complication	Mechanism	Incidence	Management
Post-operative scrotal haematoma	Bleeding from the spermatic cord stump or scrotal wound vessels	Most common (~5%)	Small: conservative (ice, compression, analgesia). Large/expanding: surgical exploration and evacuation
Wound infection	Bacterial contamination of surgical site	Uncommon (< 2%)	Antibiotics; wound care
Chronic groin pain / neuralgia	Damage to the ilioinguinal nerve (L1) running through the inguinal canal, or entrapment in scar tissue	~5–10%	NSAIDs, neuropathic pain agents (gabapentin), nerve block
Hypogonadism (biochemical)	Loss of ~50% of testicular tissue → remaining testis may not fully compensate → ↓testosterone	~10–20% develop compensated or overt hypogonadism over time	Monitor testosterone levels; TRT if symptomatic hypogonadism (fatigue, ↓libido, ↓bone density, erectile dysfunction)
Cosmetic / body image	Absent testis → psychological distress, especially in young men	Variable	Offer testicular prosthesis at time of orchidectomy or later

RPLND requires expertise and has high risk of complications ^[1].

Complication	Mechanism	Incidence	Prevention / Management
Retrograde ejaculation (most important)	Damage to the sympathetic postganglionic fibres (hypogastric plexus, T12–L3) that control antegrade ejaculation: (1) closure of bladder neck during ejaculation, (2) coordinated contraction of vas deferens/seminal vesicles. If these fibres are disrupted → semen is ejaculated backward into the bladder instead of forward through the urethra → anejaculation or "dry orgasm" → effective infertility despite normal sperm production.	Up to ~75% in non-nerve-sparing RPLND; < 5% in nerve-sparing RPLND	Nerve-sparing surgical technique — meticulous identification and preservation of the postganglionic sympathetic fibres. If retrograde ejaculation occurs: sympathomimetics (pseudoephedrine) may restore antegrade ejaculation in some patients; alternatively, sperm can be recovered from post-orgasm urine for assisted reproduction.
Chylous ascites / lymphatic leak	Disruption of the cisterna chyli or major retroperitoneal lymphatics during dissection → leakage of lymphatic fluid (chyle) into the peritoneal cavity	~2–5%	Fat-free / medium-chain triglyceride (MCT) diet; total parenteral nutrition (TPN) in severe cases; usually self-limiting
Bowel obstruction (adhesions)	Post-operative adhesion formation in the retroperitoneum	Uncommon	Conservative initially; surgical adhesiolysis if complete obstruction
Vascular injury (aorta, IVC, renal vessels)	Proximity of node-bearing tissue to great vessels; particularly challenging in post-chemo RPLND with desmoplastic reaction around vessels	Rare in experienced centres	Expert surgeon at high-volume centre
Wound complications	Large incision (midline laparotomy) → hernia, infection, seroma	Variable	Standard surgical wound care

Why Nerve-Sparing RPLND Matters So Much

These patients are young men in their 20s–30s. Retrograde ejaculation means functional infertility. Even though they already have sperm banked, the psychological impact of losing ejaculatory function is significant. Nerve-sparing technique has been one of the most important advances in testicular cancer surgery. However, it requires expert training and may not always be possible (e.g., in bulky post-chemotherapy residual disease with desmoplastic reaction encasing the nerves).

3. Complications of Chemotherapy (BEP Regimen)

BEP therapy: Bleomycin + Etoposide + Cisplatin ^[1]. Each drug has specific toxicity profiles that you must know:

Toxicity	Mechanism	Clinical Features	Prevention / Management
Nephrotoxicity (dose-limiting)	Cisplatin accumulates in renal tubular cells (particularly proximal tubule) → generates reactive oxygen species → direct tubular necrosis + renal vasoconstriction	Rising creatinine, ↓eGFR, renal magnesium/potassium/calcium wasting	Aggressive IV hydration (pre- and post-infusion) + saline loading; monitor renal function before each cycle; dose-reduce or switch to carboplatin if significant decline
Ototoxicity	Cisplatin damages outer hair cells of the cochlea (basal turn first → high-frequency hearing loss earliest) → generates free radicals → apoptosis of hair cells	High-frequency sensorineural hearing loss (initially > 4 kHz, may progress to conversational frequencies); tinnitus	Irreversible — baseline audiometry; dose-reduce if significant hearing loss; sodium thiosulfate (under investigation as otoprotectant)
Peripheral neuropathy	Cisplatin accumulates in dorsal root ganglia → damages large myelinated sensory fibres	Stocking-glove distribution paraesthesiae and numbness; may persist long after treatment	Dose-reduce or stop if severe; no proven neuroprotective agent
Severe nausea/vomiting	Stimulates the chemoreceptor trigger zone (CTZ) in the area postrema (medulla) via 5-HT3 and NK1 receptors	Acute (within 24h) and delayed (days 2–5) emesis	Triple antiemetic prophylaxis: 5-HT3 antagonist (ondansetron) + NK1 antagonist (aprepitant) + dexamethasone. Cisplatin is among the most emetogenic agents known.
Hypomagnesaemia	Cisplatin damages the ascending loop of Henle and distal convoluted tubule → impaired magnesium reabsorption	Muscle cramps, tremor, ↓reflexes, arrhythmias; can cause secondary hypokalaemia and hypocalcaemia (Mg²⁺ is needed for PTH secretion and K⁺ channel function)	IV/oral magnesium supplementation; monitor Mg²⁺ levels
Myelosuppression	Bone marrow DNA damage → impaired haematopoiesis	Anaemia, neutropenia, thrombocytopenia	G-CSF support if needed; blood product transfusion

Toxicity	Mechanism	Clinical Features	Prevention / Management
Myelosuppression (dose-limiting)	Topoisomerase II inhibition in rapidly dividing haematopoietic progenitors → DNA double-strand breaks → apoptosis	Neutropenia (nadir ~day 10–14), thrombocytopenia, anaemia	G-CSF for neutropenic fever; dose-adjust per protocol
Secondary leukaemia (treatment-related AML/MDS)	Etoposide-related leukaemia characteristically involves t(11q23) / KMT2A (MLL) rearrangements; topoisomerase II inhibition at specific genomic sites creates chromosomal translocations	Typically manifests 2–5 years after treatment; presents with cytopenias, bone marrow failure	Risk is cumulative dose-dependent; lifetime monitoring; unfortunately, treatment-related AML has poor prognosis ^[15]
Alopecia	Damage to rapidly dividing hair follicle cells	Universal hair loss (scalp, eyebrows, body hair)	Reversible after treatment completion; scalp cooling may reduce severity
Mucositis	Damage to rapidly dividing mucosal epithelial cells	Oral ulceration, dysphagia, diarrhoea	Mouth care, analgesia, nutritional support

Toxicity	Mechanism	Clinical Features	Prevention / Management
Pulmonary fibrosis (dose-limiting and potentially fatal)	Bleomycin is inactivated by the enzyme bleomycin hydrolase, which is present in most tissues except the lungs and skin. Therefore, bleomycin accumulates in the lungs → generates free radicals → oxidative damage → interstitial pneumonitis → progressive fibrosis	Dry cough, progressive dyspnoea, ↓DLCO on PFTs; bilateral basal reticular infiltrates on CXR; may progress to fatal respiratory failure	Cumulative dose limit: < 300–360 IU total; baseline + serial PFTs (DLCO); stop bleomycin if DLCO drops > 40% from baseline; avoid high-dose oxygen
Fatal interaction with high FiO₂ anaesthesia	Bleomycin-damaged lung parenchyma generates massive oxidative stress when exposed to high oxygen concentrations → acute ARDS-like picture → fatal	Acute respiratory failure during or after general anaesthesia with high FiO₂ — can occur even years after last dose	MUST inform anaesthetist of ANY prior bleomycin exposure; FiO₂ should be kept ≤ 0.3 if safely possible; this should be prominently documented in the patient's medical records
Skin toxicity	Bleomycin hydrolase also deficient in skin → accumulation	Hyperpigmentation (especially over pressure points and joints — "flagellate" linear streaks), Raynaud's phenomenon, sclerodactyly, alopecia	Cosmetic concern; usually reversible
Fever / anaphylactoid reaction	Direct drug effect (not true allergy); release of pyrogens	Febrile reaction during infusion in ~25%; very rarely anaphylactoid	Test dose before first full dose in some protocols; paracetamol pre-medication
Minimal myelosuppression	Unlike most chemo agents, bleomycin does not significantly suppress bone marrow — this is actually an advantage, as it can be added to myelosuppressive regimens without compounding that toxicity	—	—

Bleomycin and Anaesthesia — Worth Repeating

This point is so critical that it bears repeating from the management section: ANY patient who has EVER received bleomycin — even decades ago — must have this clearly documented. High FiO₂ during general anaesthesia can trigger fatal pulmonary toxicity. Every anaesthetist who manages this patient for the rest of their life must be informed. This is a classic exam question and a real-life killer.

4. Complications of Radiotherapy

Adjuvant radiotherapy can be given to seminoma in early stages but at the risk of secondary radiotherapy-induced malignancies ^[1].

Radiation toxicity is divided into acute (during/shortly after treatment) and late (months to decades after):

Complication	Mechanism	Management
Nausea / vomiting	Radiation to the para-aortic field → the upper gastrointestinal tract (stomach, duodenum) is within the treatment field → mucosal irritation → triggers vomiting via visceral afferents and CTZ	Anti-emetics (5-HT3 antagonists)
Diarrhoea	Small bowel within the radiation field → mucosal inflammation → malabsorption and increased motility	Loperamide, low-residue diet
Fatigue	Systemic inflammatory response to radiation; cytokine release (TNF-α, IL-6)	Rest, graded exercise
Radiation dermatitis	Direct damage to skin epithelium in the radiation field	Moisturising creams, avoid friction
Myelosuppression (mild)	Bone marrow within the radiation field (vertebral bodies, pelvis)	Usually mild; monitor CBC

Complication	Mechanism	Latency	Significance
Secondary malignancies	Radiation-induced DNA damage in normal tissues within/adjacent to the treatment field → somatic mutations → carcinogenesis. Risk increases over decades.	10–30+ years	Risk of secondary radiotherapy-induced malignancies ^[1] — the most important long-term concern. Sites include: GI tract (stomach, pancreas, colon), soft tissue (sarcoma), contralateral testis. The cumulative risk of second cancer is ~2× that of the general population, and continues to rise with follow-up time. This is the primary reason adjuvant RT for Stage I seminoma has fallen out of favour. ^[15]
Cardiovascular disease	Mediastinal scatter → accelerated atherosclerosis of coronary arteries, valvular disease; para-aortic RT → renal artery damage	10–20+ years	Increased risk of MI, ischaemic heart disease
Infertility / gonadotoxicity	Scatter radiation to the remaining contralateral testis → damage to spermatogonia (which are exquisitely radiosensitive — even 0.15 Gy can impair spermatogenesis)	Immediate → months	Gonadal shielding is used but cannot eliminate scatter entirely; recovery of spermatogenesis may take 1–3 years
Renal damage	If kidneys are partially within the field → radiation nephritis → chronic kidney disease	Months → years	Careful treatment planning with modern conformal techniques to minimise renal dose
Peptic ulcer disease	Radiation damage to gastric/duodenal mucosa	Weeks → months	PPI prophylaxis; usually self-limiting

5. Long-Term Survivorship Complications

This is arguably the most important section for testicular cancer — because the vast majority of patients are cured and survive for decades. The term "cancer survivor" is particularly relevant here.

Type	Mechanism	Risk	Timing
Contralateral testicular cancer	Shared genetic/developmental risk factors (testicular dysgenesis syndrome); radiation scatter to contralateral testis	2–5% lifetime risk	Any time (even decades later)
Treatment-related AML/MDS	Etoposide → t(11q23) rearrangements; alkylating agents (cisplatin) → complex karyotype	~0.5–1% cumulative	2–10 years post-treatment (etoposide-related peaks at 2–5 years) ^[15]
Solid second cancers (post-RT)	Secondary radiotherapy-induced malignancies ^[1] — GI cancers (stomach, pancreas, colon), soft tissue sarcomas, renal cancers	~2× general population; risk continues rising with time	10–30+ years
Solid second cancers (post-chemo)	Cisplatin/etoposide-related DNA damage in normal somatic cells	Modestly increased (smaller risk than post-RT)	10+ years

Risk Factor	Mechanism	Magnitude
Cisplatin-related endothelial damage	Cisplatin causes chronic endothelial dysfunction, dyslipidaemia, and direct vascular injury → accelerated atherosclerosis	~1.5–2× increased risk of cardiovascular events
Radiation-related vascular damage	Intimal proliferation, fibrosis of coronary and great vessel walls	~2–3× risk (particularly post-mediastinal RT)
Metabolic syndrome	Hypogonadism post-orchidectomy → ↑visceral fat, insulin resistance, dyslipidaemia; cisplatin-related renal Mg²⁺ wasting	Increased risk of T2DM, metabolic syndrome
Raynaud's phenomenon	Bleomycin-related vasospasm of digital arteries (small-vessel endothelial damage)	~10–40% of bleomycin-treated patients; may persist long-term
Thromboembolic disease	Cisplatin → endothelial activation, ↑platelet aggregation, ↑thrombotic tendency	↑ risk of DVT, PE, arterial events during and shortly after treatment

Cardiovascular disease is the leading non-cancer cause of death in testicular cancer survivors. This is why lifestyle counselling (smoking cessation, exercise, healthy diet) and monitoring of cardiovascular risk factors are essential components of survivorship care.

Complication	Mechanism	Timeline	Management
Impaired spermatogenesis at baseline	Testicular tumours are associated with gonadal dysgenesis and ~50% of men have some degree of underlying impairment of spermatogenesis ^[1]	At diagnosis (pre-treatment)	Cryopreservation of sperm ^[1] before any treatment
Further deterioration after orchidectomy	Semen quality may further deteriorate following removal of affected testis ^[1] — loss of ~50% of germ cell mass	Post-orchidectomy	Sperm banking pre-op if possible
Chemotherapy-related azoospermia	Cisplatin and etoposide are gonadotoxic → damage spermatogonial stem cells → temporary or permanent azoospermia	During and post-chemo	Recovery of spermatogenesis occurs in ~50–80% of patients within 2–5 years after BEP; alkylating agents are more permanently damaging
Radiation-related azoospermia	Spermatogonia are among the most radiosensitive cells in the body (even doses as low as 0.15 Gy impair spermatogenesis)	During and post-RT	Gonadal shielding; recovery over 1–3 years possible if dose low
Hypogonadism (↓testosterone)	Loss of one testis + potential damage to remaining testis from chemo/RT → compensated (↑LH, normal testosterone) or overt hypogonadism (↓testosterone)	Gradual; may develop years later	Monitor testosterone, LH, FSH annually; TRT if symptomatic
Leydig cell damage	Leydig cells are more radioresistant than germ cells but still susceptible to high-dose chemotherapy → ↓testosterone	Post-treatment	TRT if indicated

Testicular cancer survivors treated with cisplatin-based chemotherapy have a significantly increased risk of metabolic syndrome (central obesity + dyslipidaemia + hypertension + insulin resistance):

Component	Mechanism
Central obesity	Hypogonadism → ↓testosterone → altered body fat distribution (visceral > subcutaneous)
Dyslipidaemia	Cisplatin-related endothelial dysfunction; hypogonadism → ↓HDL, ↑LDL, ↑triglycerides
Insulin resistance / T2DM	Hypogonadism + obesity → insulin resistance; cisplatin may have direct pancreatic β-cell toxicity
Hypertension	Cisplatin-related nephrotoxicity → chronic renal dysfunction → salt-water retention; vascular endothelial damage

Prevalence of metabolic syndrome in testicular cancer survivors is approximately 20–30%, compared to ~10% in age-matched controls. Annual screening and aggressive risk factor management are essential.

Type	Mechanism	Incidence	Outcome
Peripheral neuropathy	Cisplatin accumulates in dorsal root ganglia → demyelination and axonal degeneration of large sensory fibres	~20–40% during treatment; ~10–20% have persistent symptoms	Stocking-glove numbness, paraesthesiae; may be permanent
Ototoxicity / tinnitus	Cisplatin → outer hair cell destruction in basal turn of cochlea	~20–40% have some high-frequency hearing loss	Irreversible; some patients require hearing aids
Cognitive changes ("chemobrain")	Poorly understood; possibly cisplatin-related microvascular damage to CNS, inflammatory cytokine effects on hippocampus	Subtle; reported by ~15–25% of survivors	Concentration difficulties, memory impairment; usually mild

Complication	Mechanism	Monitoring
Bleomycin pulmonary fibrosis	As detailed above — bleomycin accumulates in lung due to absence of bleomycin hydrolase → free radical damage → irreversible fibrosis	PFTs (DLCO) during treatment; lifetime awareness for anaesthetic risk
Restrictive lung disease	Post-fibrosis → reduced lung compliance → ↓FVC, ↓TLC	Annual PFTs if symptomatic
Exertional dyspnoea	Even subclinical bleomycin lung damage → reduced exercise tolerance	Cardiopulmonary exercise testing if symptomatic

Complication	Mechanism	Monitoring
Chronic kidney disease	Cisplatin → direct proximal tubular necrosis + glomerular damage → ↓GFR (typically mild-moderate decline of 15–30%)	Monitor eGFR/creatinine annually
Electrolyte wasting	Cisplatin damages tubular reabsorption mechanisms → persistent magnesium, potassium, calcium wasting	Monitor electrolytes; supplement as needed
Hypertension	Renovascular damage → RAAS activation → salt/water retention	Blood pressure monitoring

These are often underappreciated but extremely important in the context of young men with cancer:

Complication	Context	Intervention
Anxiety and depression	Diagnosis of cancer in a young person; fear of recurrence (especially during surveillance); body image concerns (loss of testis)	Psychological support, counselling, referral to psycho-oncology
Body image disturbance	Missing testis, surgical scars, gynaecomastia, weight gain, alopecia	Testicular prosthesis; counselling; support groups
Sexual dysfunction	Erectile dysfunction (hypogonadism, psychological); retrograde ejaculation (post-RPLND); loss of libido (↓testosterone)	TRT, PDE5 inhibitors; psychosexual counselling
Fertility anxiety	Even with sperm banking, patients worry about future fertility; some patients present without prior banking	Early fertility counselling; IVF/ICSI with banked sperm; referral to reproductive medicine
Relationship difficulties	Sexual dysfunction, fertility concerns, psychological burden of cancer diagnosis	Couples counselling; open communication encouraged
Return-to-work challenges	Treatment duration (3–4 months for BEP × 3–4 cycles); fatigue; concentration difficulties	Occupational therapy; phased return to work
Fear of contralateral tumour	2–5% lifetime risk of second testicular cancer; surveillance generates ongoing anxiety	Testicular self-examination education; reassurance about curability

While not strictly a "complication," relapse is an important adverse outcome:

Feature	Detail
Relapse > 2 years is rare ^[2]	Most relapses occur within first 1–2 years; hence surveillance is most intensive during this period
Late relapse ( > 2 years)	Occurs in < 5% of cases; tends to be chemoresistant (often mature teratoma with somatic transformation)
Salvage success	First salvage chemotherapy (TIP/VeIP) achieves long-term remission in ~50% of relapsed patients; high-dose chemo + autologous SCT for further relapse ^[15]
Growing teratoma syndrome	Enlarging mass during/after chemo with normalising markers → teratoma (chemoresistant) → requires surgical resection

Timeframe	Key Complications
At diagnosis	Subfertility (~50% baseline); local symptoms; metastatic complications (back pain, dyspnoea, neurological)
Peri-operative (orchidectomy)	Scrotal haematoma; wound infection; inguinal neuralgia
During chemotherapy (weeks–months)	Nephrotoxicity, ototoxicity, neuropathy, N/V (cisplatin); neutropenia, alopecia (etoposide); pulmonary toxicity (bleomycin); thromboembolic events
Peri-RPLND	Retrograde ejaculation; chylous ascites; vascular injury; bowel obstruction
During RT (weeks)	Nausea, diarrhoea, fatigue, radiation dermatitis
Early post-treatment (months–years)	Recovery of spermatogenesis; persistence of neuropathy/ototoxicity; Raynaud's
Late (5–30+ years)	Secondary malignancies (AML/MDS at 2–5y; solid second cancers at 10–30y); cardiovascular disease; metabolic syndrome; chronic renal impairment; hypogonadism; pulmonary fibrosis; contralateral testicular cancer
Lifelong	Psychosocial (anxiety, depression, body image, sexual dysfunction, fertility concerns); anaesthetic risk (bleomycin lung)

High Yield Summary

Disease complications: Intratumoral haemorrhage (mimics torsion), ureteric obstruction (retroperitoneal LNs), haemorrhagic brain mets (choriocarcinoma), hyperthyroidism (very high β-hCG has TSH-like activity), gynaecomastia (β-hCG → oestrogen).

Orchidectomy: Usually minimal morbidity. Most common = scrotal haematoma. Long-term: hypogonadism (monitor testosterone).

RPLND: Most important = retrograde ejaculation (damage to sympathetic postganglionic fibres T12–L3). Prevented by nerve-sparing technique (reduces rate from 75% to < 5%).

BEP toxicities: Cisplatin = nephrotoxicity (hydration), ototoxicity (irreversible), neuropathy, severe N/V. Etoposide = myelosuppression, secondary AML/MDS (t(11q23), peaks 2–5 years). Bleomycin = pulmonary fibrosis (cumulative dose < 300 IU; DLCO monitoring; NEVER high FiO₂ — even years later).

Radiotherapy: Secondary malignancies (the main reason RT is falling out of favour for Stage I seminoma); cardiovascular disease; gonadotoxicity.

Survivorship (most important): Cardiovascular disease (leading non-cancer cause of death); metabolic syndrome (20–30%); secondary malignancies; persistent neuropathy/ototoxicity; infertility/hypogonadism; psychosocial distress. Annual screening and risk factor management are essential.

Bleomycin-anaesthesia rule: ANY prior bleomycin exposure = lifelong high FiO₂ contraindication during anaesthesia. MUST inform every anaesthetist.

Active Recall - Complications of Testicular Cancer

References

^[1] Senior notes: felixlai.md (Testicular cancer — Treatment section, Paraneoplastic syndrome) ^[2] Senior notes: Ryan Ho Urogenital.pdf (Section 11.2.5 Testicular Tumours, p.235–236) ^[9] Senior notes: maxim.md (Testicular tumour — Management section) ^[15] Senior notes: Ryan Ho Haemtology.pdf (Section 5.2.2 Complications and Prognosis of HSCT, p.156; Section 3.5.1 late complications of lymphoma treatment, p.96) ^[16] Senior notes: Ryan Ho Respiratory.pdf (Section 3.6.2 Secondary Tumours of the Lungs, p.151)